

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



友芝友生物製藥

WUHAN YZY BIOPHARMA CO., LTD.

武漢友芝友生物製藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2496)

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

RESIGNATION OF SUPERVISOR

The board of directors (the “**Board**”) of Wuhan YZY Biopharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Dr. Wang Tao (王濤) (“**Dr. Wang**”) resigned as an employee representative supervisor of the Company with effect from December 31, 2025 due to personal career development reasons.

Dr. Wang has confirmed that he has no disagreement with the Board and the supervisory committee of the Company (the “**Supervisory Committee**”) and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited.

The Company would like to take this opportunity to express its sincere gratitude to Dr. Wang for his contribution to the Company during his tenure of service.

APPOINTMENT OF SUPERVISOR

The Board is pleased to announce that Dr. Shi Jian (石劍) (“**Dr. Shi**”), the director of the Translational Medicine Department of the Company, was democratically elected as an employee representative supervisor of the second session of the Supervisory Committee on December 31, 2025. Pursuant to the Company’s articles of association, employee representative supervisors are elected democratically by the general meeting of employee representative, the general meeting of employees or in other ways, and are not subject to the approval of the Shareholders.

The term of office of Dr. Shi became effective from December 31, 2025 and will expire until the end of the second session of the Supervisory Committee. Dr. Shi will not receive any remuneration from the Company as an employee representative supervisor.

The biographical details of Dr. Shi are set out below:

Dr. Shi was born in 1982, aged 43. Dr. Shi has over 15 years of research experience in the development of therapeutic antibodies, fusion proteins, and protein subunit vaccines within the biopharmaceutical industry. Dr. Shi obtained his bachelor of science degree in Biological Sciences from Wuhan University in 2004 and a Ph.D. in Microbiology from Wuhan University in 2014. From 2014 to 2018, Dr. Shi worked at the Wuhan Institute of Virology of the Chinese Academy of Sciences. Dr. Shi joined the Company in 2018 and has held various positions, including scientist in the Antibody Engineering Technology Department of the Research and Development (R&D) Centre, deputy director and director of the Early Development Research Department of the R&D Centre, director of the Translational Medicine Department of the R&D Centre, and concurrently serves as the chairman of the Company's Labor Union. In addition, Dr. Shi was selected as an innovative talent under the "3551 Optics Valley Talent Program" in Wuhan in 2023.

Dr. Shi has confirmed that, save as disclosed above, as at the date of this announcement, he (i) did not hold any directorship in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) did not have other major appointments or professional qualifications; (iii) did not have any relationship with any director, supervisor, senior management, substantial shareholder or controlling shareholder (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) of the Company; (iv) did not hold any other positions with the Company or other members of the Group; and (v) did not have any other interests in any shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, the Board is not aware of other information in respect of Dr. Shi's appointment as an employee representative supervisor of the Company that is required to be disclosed pursuant to the requirements set out in Rule 13.51(2)(h) to (v) of the Listing Rules, nor is there any matter that needs to be brought to the attention of the Shareholders.

By order of the Board
Wuhan YZY Biopharma Co., Ltd.
Dr. Zhou Pengfei

Chairman of the Board, Executive Director and Chief Executive Officer

Wuhan, PRC, December 31, 2025

As at the date of this announcement, the Board comprises Dr. Zhou Pengfei and Mr. Wen Zhicheng as executive directors; Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu and Mr. Xie Shouwu as non-executive directors; and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive directors.